London, UK – March 4, 2025 – Vidac Pharma Holding PLC (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage biopharmaceutical company pioneering novel oncology treatments, is pleased to announce its participation in the First Pediatric Brain Tumor Research Meeting on March 9, 2025, in Jerusalem, Israel.
This landmark event will bring together leading international researchers, clinicians, and industry experts to share insights and advancements in pediatric brain tumor research. Dr. Herzberg will present findings from Vidac Pharma’s latest breakthrough, underscoring the company’s commitment to developing innovative treatment approaches.
As part of a compassionate treatment program for a five-year-old child, Vidac Pharma’s investigational drug VDA-1102 was successfully formulated to cross the blood-brain barrier (BBB) and was detected within the tumor at potentially therapeutic concentrations. “This marks a significant milestone, opening new possibilities for groundbreaking therapies targeting brain diseases,” said Dr. Herzberg. “This discovery represents an exciting opportunity to transform treatment options for children battling these devastating conditions, while Vidac Pharma remains dedicated to advancing clinical programs in oncodermatology.”
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.